We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
Active Needle is a medical device company that aims to prevent the problem of needle placement errors in ultrasound-guided needle interventional procedures. The technology allows for precision needle targeting.
days to go: Expired investment: £147,514
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go: Expired investment: £1,146,318
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go: Expired investment: £543,670
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go: Expired investment: £451,506
Cellmed is an immuno-oncology company that are developing treatments for ovarian cancer.  Their lead product PROCURE a dendritic cell vaccine and they are now looking to expand the treatment to target solid tumors.    
days to go: Expired investment: £520,294
Combat Medical have created an innovative method to treat bladder cancer by using heated chemotherapy. By heating the treatment the membrane is more permeable and is able to penetrate further. 
days to go: Expired investment: £1,725,220
Reducing the cost of orthopaedic equipment by using compression screws and titanium maxiangle locking plates. DC Surgical Supplies have acquired an exclusive license with Palmer & Baker with the aim of helping the NHS cut the cost of purchasing regular-use equipment by as much as 35%. Their product is CE Certified and has been featured in The Telegraph.
days to go: Expired investment: £99,000
Providing dental professionals with an online Personal Development Plan for their Continuing Professional Development. Dentinal Tubules currently has more than 2,100 individuals registered to use the service and over 2,700 dental practice professionals that are paying for a subscription. Dentinal Tubules hosts more than 1,500 educational and certified videos to help with a professional's CPD, in addition they also offer live courses, a livestream and an annual congress. Investments will be used to enhance, develop and bring the technology in-house.
days to go: Expired investment: £155,820
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph